05 Nov 7 Common Causes of Hypotension
Dehydration, medications, heart and hormonal conditions, pregnancy and even meals can lower blood pressure. Here are 7 common causes of hypotension. ...
Dehydration, medications, heart and hormonal conditions, pregnancy and even meals can lower blood pressure. Here are 7 common causes of hypotension. ...
Blood Pressure Notice: If your blood pressure is elevated and you have chest pain, shortness of breath, back pain, numbness or weakness, vision changes, or difficulty speaking, call 911 or your local emergency number immediately. This article is for general education and is not a substitute for diagnosis or treatment by a qualified healthcare provider. Do not start, stop, or change blood pressure medication without your provider's guidance. Providers linked here are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
Prof. Moo-Yong Rhee[/caption]
Professor Moo-Yong Rhee MD, PhD.
Cardiology, Dongguk University Ilsan Hospital
College of Medicine, Dongguk University
Goyang-si, Gyeonggi-do, Korea
MedicalResearch.com: What is the background for this study?
Response: Hypertension remains one of the leading causes of cardiovascular morbidity and mortality worldwide. Major challenges in its initial treatment include therapeutic inertia, reliance on stepwise dose escalation of single agents, and reduced adherence due to dose-related adverse effects. These limitations often delay optimal blood pressure control.
To address these issues, the concept of low-dose combination therapy was proposed, based on the rationale that combining multiple agents at lower doses may enhance efficacy while minimizing side effects. Although several studies have supported this concept, systematic translational research and confirmatory clinical trials were needed before widespread clinical implementation.
The recently completed APOLLO-301 and APOLLO-302 trials were confirmatory, randomized, phase 3 studies designed to evaluate the efficacy and safety of a single-pill ultra-low-dose triple combination therapy, conducted in accordance with regulatory standards. This formulation combined three antihypertensive agents (amlodipine (1.67 mg), losartan (16.67 mg), and chlorthalidone (4.17 mg)) each at approximately one-third of its standard dose. The triple combination was directly compared with standard-dose monotherapy (amlodipine 5 mg or losartan 50 mg).
After 8 weeks of treatment, the ultra-low-dose triple combination achieved blood pressure reductions comparable to those of amlodipine 5 mg and significantly greater than those of losartan 50 mg, while maintaining good tolerability. These findings support the potential role of ultra-low-dose triple therapy as an effective initial treatment strategy for patients with mild-to-moderate hypertension.
Dr. Minji Jung[/caption]
Minji Jung PharmD, PhD
Postdoctoral Research Fellow in Epidemiology
Department of Urology
Stanford University Medical Center
Stanford, CA
MedicalResearch.com: What is the background for this study?
Response: Hypertension is a well-established risk factor for kidney cancer, and previous studies have suggested potential links between antihypertensive medications and kidney cancer risk. However, distinguishing the effects of the medications from those of hypertension itself has been challenging. Our meta-analysis systematically evaluated different classes of antihypertensive drugs while accounting for hypertension.
Dr. Layton[/caption]
Anita T. Layton PhD
Canada 150 Research Chair in Mathematical Biology and Medicine
Professor of Applied Mathematics, Computer Science, Pharmacy and Biology
University of Waterloo
MedicalResearch.com: What is the background for this study? Why did you decide to examine a potential link between potassium intake and lowering blood pressure?
Response: Our diet is so very different from our long-ago ancestors, especially in terms of sodium-to-potassium ratio. We eat so much sodium and so little potassium, that ratio is reversed in our ancestors as well as people in isolated tribes, where high blood pressure is very rare. So, let's figure out why and thus this stud
MedicalResearch.com: In layman's terms, how the ratio of potassium to sodium can both negatively and positively impact the body?
Response: Having more potassium in your body would encourage the kidneys to pee out more sodium (and water), which lowers blood pressure.
RAS inhibitors are used to decrease blood pressure and prevent its deleterious effects in the heart and brain such as stroke....
Dr. Bujold[/caption]
Emmanuel Bujold, Reproduction
Mother and Child Health Unit
CHU De Québec-Université Laval Research Center
Université Laval
Québec, QC Canada
MedicalResearch.com: What is the background for this study? Would you briefly describe what is meant by preeclampsia?
Response: Preeclampsia is a complication of the second half of pregnancy, manifesting as high blood pressure and renal dysfunction. The only current treatment is to deliver the baby before it becomes complicated by damage to maternal organs or fetal distress.
A few years ago, we demonstrated that aspirin started in the 1st trimester can prevent the majority of preeclampsias in pregnant women at risk. It has therefore become urgent to identify pregnant women at risk as early as the 1st trimester.
It is your lifestyle that determines your blood pressure levels. Your nutritional intake and the level of activity have a significant part as well.
First, monitor what you eat. Try to have your daily intake equally distributed among fruits, vegetables, whole grain and lean proteins. Cutting back on salty food can also do great magic.
In terms of physical activity, even minor adjustments can yield significant results. Moreover, a consistent practice of physical activity, such as brisk walking or swimming, may lower your blood pressure over a period of time. Remember, you don’t have to run a marathon – being dedicated is what you should focus on doing.
With these modifications, you are moving proactively towards normalized blood pressure levels.
Esa M. Davis, M.D., M.P.H , F.A.A.F.P
Professor of Medicine and Family and Community Medicine
Associate Vice President of Community Health and
Senior Associate Dean of pPopulation Health and Community Medicine
University of Maryland School of Medicine
Dr. Davis joined the U.S. Preventive Services Task Force in January 2021
MedicalResearch.com: What is the background for this study?
Response: Hypertensive disorders of pregnancy, including gestational hypertension, preeclampsia, and eclampsia, are among the leading causes of serious complications and death for pregnant people in the United States.
Pregnant women and pregnant people of all genders should have their blood pressure measured at each prenatal visit to help find and prevent serious health issues related to hypertensive disorders of pregnancy.
Dr. McLoughlin Brady[/caption]
Tammy M. Brady, MD, PhD (she/her/hers)
Vice Chair for Clinical Research, Dept of Pediatrics
Associate Director, Welch Center for Prevention, Epidemiology, and Clinical Research
Associate Professor of Pediatrics, Division of Pediatric Nephrology
Medical Director, Pediatric Hypertension Program
Johns Hopkins University
Baltimore, MD 21287
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Accurate BP measurement is key to identification and treatment of hypertension which serves ultimately to prevent cardiovascular disease. Our study describes substantial measurement error that can occur in a common office and home BP measurement scenario: use of a regular cuff size for all individuals regardless of arm size. Many office triage measurements occur without individualized cuff selection and most home BP devices come with one cuff size – and our study shows that using a regular cuff size for people who have larger arms – those who require a large adult cuff or an extra-large adult cuff – can lead to blood pressure readings that are almost 5 and 20 mmHg greater than their actual BP, respectively. Those require a small adult cuff can have BP readings that are almost 4 mmHg lower than their actual BP.
Dr. Sundström[/caption]
Johan Sundström, MD, PhD
Professor of Epidemiology at Uppsala University
Professorial Fellow at The George Institute for Global Health
Cardiologist at Uppsala University Hospital
MedicalResearch.com: What is the background for this study?
Response: High blood pressure, hypertension, is a growing global health challenge. Over the last 30 years, the number of people with hypertension has doubled, and it is estimated that around a third of adults aged 30-79 have the condition - a total of 1.28 billion people worldwide. Untreated hypertension can lead to kidney disease, heart disease, and stroke, accounting for 11.3 million deaths in 2021 alone. A small minority get their blood pressure under control with drug therapy, and some studies indicate that as little as half are taking their blood pressure medications as intended. Is this because the drugs' effectiveness and side effects differ between different individuals? If so, there would be a substantial risk that patients will not get their optimal medication on the first try, with poor blood pressure lowering and unnecessary side effects as a result.
In a new clinical trial in Sweden, it was studied whether there is an optimal blood pressure medication for each person, and thus a potential for personalized blood pressure treatment. In the study, 280 people with high blood pressure tried out four different blood pressure drugs on several different occasions over a total of one year.
Prof. Rahimi[/caption]
Kazem Rahimi FRCP, DM, MSc, FESC
Professor of Cardiovascular Medicine and Population Health
University of Oxford
Consultant cardiologist
Oxford University Hospitals NHS Trust
MedicalResearch.com: What is the background for this study?
Response: The prevalence of hypertension has been rising worldwide. To mitigate the burden, identifying the modifiable environmental risk factors of hypertension and developing preventive interventions constitute important public health priorities. Despite the biological plausibility of the link between road traffic noise and the risk of hypertension, the quality of relevant evidence has been low, and the role of air pollution has been uncertain.
Prof. McManus[/caption]
Richard McManus MA PhD MBBS FRCGP FRCP
Professor of Primary Care
Dr. McManus chairs the Blood Pressure Monitoring Working Party
of the British Hypertension Society
Nuffield Department of Primary Care Health Sciences
MedicalResearch.com: What is the background for this study?
Response: About one in ten people who are pregnant develop high blood pressure and almost half of these go onto to have pre-eclampsia. Many pregnant women and individuals are already measuring their own blood pressure – well over half of those with high blood pressure in a recent large survey in the UK but until recently there were no data to support this.
Dr. Palatini[/caption]
Paolo Palatini, M.D.
Professor of Internal Medicine
University of Padova
Padova, Italy
MedicalResearch.com: What is the background for this study?
Response: Up to now doctors measured blood pressure (BP) on standing only in elderly people on pharmacological treatment with the purpose of detecting orthostatic hypotension. In young-to-middle-age people BP is currently measured only in the lying or the sitting posture.
Our starting point was that young borderline hypertensive people have an increased sympathetic activity and thus they might be hyperreactive to physical stimuli such as assuming the orthostatic posture which may be deleterious in the long run. This hypothesis was tested in the HARVEST, a study initiated in Italy in 1990, in which over 1200 young patients screened for stage 1 hypertension were enrolled.
Dr. Launer[/caption]
Lenore J. Launer, Ph.D.
Chief, Laboratory of Epidemiology and Population Sciences
Intramural Research Program, National Institute on Aging.
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Identifying early risk factors and early changes in the brain will have a major impact on future clinical and public health priorities related to the looming epidemic of dementia. Several studies based on older populations suggest mid-life is an important period to start prevention measures. To date control of blood pressure levels has been the most robust and promising candidate to target for prevention of future cognitive impairment. Although several studies have looked at levels of blood pressure and risk for cognitive impairment, it was not known whether trajectories from young adulthood to middle age studies provided additional information about risk. To investigate possible biomarkers of future risk, we chose to examine the association of the mean arterial blood pressure trajectories to indicators of pathology seen on MRI and that are associated with cognition.
We highlight the results of the mean arterial blood pressure (MAP) measure, which is an integrated measure of systolic and diastolic blood pressure.
Dr. LaMonte[/caption]
Michael J. LaMonte, PhD, MPH
Research Professor (epidemiology)
Department of Epidemiology and Environmental Health
School of Public Health and Health Professions
Women’s Health Initiative Northeast Regional Center
University at Buffalo – SUNY
Buffalo, NY 14214
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. LaMonte: The rationale for this study was based on existing study results showing
Dr. van Dalen[/caption]
Jan Willem van Dalen, PhD
Department of Neurology
Donders Institute for Brain, Behaviour and Cognition
Radboud University Medical Centre Nijmegen
Department of Neurology
The Netherlands3Department of Public and Occupational Health
Amsterdam UMC, University of Amsterdam, Amsterdam
MedicalResearch.com: What is the background for this study?
Response: Although high systolic blood pressure in midlife has consistently been reported as a condition that increases the risk of developing dementia in old age, reports regarding this relationship in older people have been inconsistent. One potential reason for this, is that the relationship between systolic blood pressure and dementia in later life may be U-shaped, meaning that both individuals with low and with high systolic blood pressure are at increased incident dementia risk.
This study combined data from several longitudinal cohort studies specifically designed to study incident dementia in older people, to investigate whether these U-shaped relationships exist, and in which age ranges they appear. We included more than 16,500 people aged 60 and older, with over 2,700 incident dementia cases.
Also, we aimed to investigate whether these observational associations might be caused by confounding, differences in mortality, or result from opposite relationships between certain subgroups of individuals.
Dr. Chan - UPMC image[/caption]
Stephen Chan, M.D., Ph.D.
Professor of Medicine
Director of the Vascular Medicine Institute
at Pitt and UPMC
MedicalResearch.com: What is the background for this study?
Response: Pulmonary hypertension (PH) is a type of high blood pressure that occurs in the vessels that transport blood from the heart to the lungs. As the disease progresses and the heart must strain harder against these high pressures, it can lead to heart failure, multi-organ dysfunction and death. PH affects people of all ages but hits young women more often than men.
Pulmonary hypertension is an example of a rare disease where there is an unmet need for new treatments, given its devastating consequences. Repurposing drugs that are already in use for other purposes can dramatically cut down the time and cost of developing treatments for rare diseases like PH. But a pipeline to predict and test for drugs in this way for PH and other rare diseases has not been described.
Dr. Cole[/caption]
Megan B. Cole, PhD, MPH
Assistant Professor | Dept. of Health Law, Policy, & Management
Co-Director | BU Medicaid Policy Lab
Boston University School of Public Health
Boston, MA 02118
MedicalResearch.com: What is the background for this study?
Response: Under the Affordable Care Act, states were given the option to expand Medicaid eligibility to nonelderly adults with incomes up to 138% of the federal poverty level, where in January 2014, 25 states plus Washington, DC expanded eligibility, with 13 additional states expanding thereafter. State Medicaid expansion decisions were particularly consequential for federally qualified health centers (FQHCs), which serve nearly 30 million low-income, disproportionately uninsured patients across the US.
We know from earlier work that in the shorter-term, Medicaid expansion was associated with improvements in quality of care process measures and FQHC service capacity. However, we conducted the first known nationally representative study to examine how Medicaid expansion impacted key chronic disease outcome measures at FQHCs over the longer-term by looking at changes five years after implementation, including changes by race/ethnicity.
Dr. Ribeiro[/caption]
Fernando Ribeiro PhD
School of Health Sciences
Institute of Biomedicine - iBiMED
University of Aveiro
Aveiro, Portugal
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Resistant hypertension is a puzzling problem without a clear solution. The available treatment options to lower blood pressure, namely medication and renal denervation, have had limited success, making nonpharmacological strategies good candidates to optimize the treatment of this condition.
Exercise training is consistently recommended as adjuvant therapy for patients with hypertension, yet, it is with a great delay that the efficacy of exercise training is being tested in patients with resistant hypertension.
Having that in mind, the EnRicH trial was designed to address whether the benefits of an exercise intervention with proven results in hypertensive individuals are extended to patients with resistant hypertension, a clinical population with low responsiveness to drug therapy. Exercise training was safe and associated with a significant and clinically relevant reduction in 24-hour, daytime ambulatory, and office blood pressure compared with control (usual care).
Dr. Lopez[/caption]
Maria Luisa S. Sequeira Lopez, MD, FAHA
Harrison Distinguished Professor in Pediatrics and Biology
University of Virginia
Charlottesville, VA 22908
MedicalResearch.com: What is the background for this study?
Response: The renin-angiotensin system (RAS) is crucial in the regulation of the blood pressure (BP). Synthesis and secretion of renin is the key regulated event in the operation of the RAS.
One of the main mechanisms that control renin synthesis and release is the baroreceptor mechanism whereby a decrease in blood pressure results in increased release of renin by juxtaglomerular (JG) cells.
In spite of its enormous importance, the nature and location of the renal baroreceptor was still unknown. This was due in great part to the lack of appropriate in vitro and in vivo models to confidently allow tracking of the fate and isolation of renin cells, and the lack of tools to study the chromatin in scarce cells.
Dr. Hripcsak[/caption]
George Hripcsak, MD, MS.
Chair and Vivian Beaumont Allen Professor of Biomedical Informatics
Department of Biomedical Informatics,
Columbia University Irving Medical Center
New York, NY
MedicalResearch.com: What is the background for this study?
Response: ACE inhibitors and ARBs are anti-hypertension drugs that have related yet distinct mechanisms of action, and they are both recommended as first-line therapies for treating hypertension. There have been no large head-to-head comparisons of ACE inhibitors and ARBs, although there are several studies with limited size and often restricted (e.g., high-risk) populations. While there are some conflicting results in the literature, the current evidence seems to indicate that they are similar in effectiveness but that ACE inhibitors have more side effects (e.g., cough and angioedema).
Dr. Nation[/caption]
Daniel A. Nation, Ph.D.,
Associate Professor of Psychological Science
Institute for Memory Impairments and Neurological Disorders
University of California, Irvin
MedicalResearch.com: What is the background for this study?
Response: Hypertension is a risk factor for cognitive decline and dementia, and treatment of hypertension has been linked to decreased risk for cognitive impairment.
Prior studies have attempted to identify which specific type of antihypertensive treatment conveys the most benefit for cognition, but findings have been mixed regarding this question. We hypothesized that antihypertensive drugs acting on the brain angiotensin system may convey the greatest benefit since they affect the brain angiotensin system that has been implicated in memory function.
Dr. Wong[/caption]
John B. Wong, M.D.
Chief Scientific Officer
Vice chair for Clinical Affairs
Chief of the Division of Clinical Decision Making and
Primary care Clinician
Department of Medicine at Tufts Medical Center
MedicalResearch.com: What is the background for this study?
Response: Hypertension affects nearly half of all adults in the United States and is a major risk factor for many serious health conditions. Fortunately, by screening all adults for hypertension, clinicians can improve their patient’s health. The Task Force continues to recommend screening all adults for hypertension so that they can get the care they need to help prevent health conditions such as heart attack, stroke, and kidney failure.
Dr. Durgan[/caption]
David J. Durgan, PhD
Department of Anesthesiology
Baylor College of Medicine
Houston, TX
MedicalResearch.com: What is the background for this study?
Response: Our lab and others had previously shown that gut dysbiosis is not only associated with hypertension, but actually plays a causal role. For example we have shown in both a genetic model of hypertension as well as an obstructive sleep apnea induced model of hypertension, that transplantation of their dysbiotic microbiota into normotensive recipients induced elevations in blood pressure.
With this understanding our focus shifted to two new questions
1) How can we manipulate the microbiota to improve/prevent hypertension, and
2) What are the signals originating from the microbiota that have the capability to influence host blood pressure?
These questions lead to the experimental design of this study.
Prof. D'Aiuto[/caption]
Francesco D’Aiuto
Professor/Hon Consultant
Head of Periodontology Unit
UCL Eastman Dental Institute
MedicalResearch.com: What is the background for this study?
Response: This study was set out to further our understanding of the link between gum disease and high blood pressure. Recent evidence suggested that individuals with gum disease had a 20-70% increased risk of hypertension and systemic inflammation seemed to be a driver in mediating this association. Further research on the matter was needed. We recruited two relatively large groups of otherwise healthy participants (without a confirmed diagnosis of hypertension) who had gum disease one and healthy gums the other.
We found that diagnosis of periodontitis (gum disease) was consistently linked to higher systolic blood pressure independent of other cardiovascular risk factors.
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Hypertension in children is a growing problem around the world, but when diagnosing hypertension, most of the time blood pressure is only measured in one arm. Our study showed that children can have a blood pressure difference between arms that may be considered significant in a clinical setting. One in four children had a difference between left and right arms that could mean that blood pressure appears normal in one arm, but in the other arm it would be classified as a high blood pressure. This means that if a doctor measures blood pressure in one arm only, a diagnosis of high blood pressure could be missed.
Kathryn Foti, PhD, MPH
Postdoctoral fellow
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health
MedicalResearch.com: What is the background for this study?
Response: The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure (BP) in Chronic Kidney Disease (CKD) provides recommendations for the management of BP in individuals with nondialysis CKD, incorporating new evidence since the publication of its previous guideline in 2012.
The 2021 KDIGO guideline recommends a target systolic BP <120 mmHg based on standardized office BP measurement. This BP goal is largely informed by the findings of the SPRINT trial which found targeting SBP <120 mmHg compared with <140 mmHg reduced the risk of cardiovascular disease by 25% and all-cause mortality by 27%. The benefits were similar for participants with and without CKD.
In our study, we sought to examine the potential implications of the 2021 KDIGO guideline for BP lowering among US adults with CKD compared to the 2012 KDIGO guideline (target BP ≤130/80 mmHg in adults with albuminuria or ≤140/90 mmHg or under without albuminuria) and the 2017 American College of Cardiology/American Heart Association (target BP <130/80 mmHg) guideline. Additionally, we determined implications of the 2021 KDIGO guideline for angiotensin converting enzyme inhibitor (ACEi) or angiotensin II-receptor blocker (ARB) use for those with albuminuria (recommended at systolic BP ≥120 mmHg) compared to the 2012 KDIGO guideline (recommended at BP >130/80 mmHg).